New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
08:37 EDTBRLIBio-Reference Labs reports Q1 EPS 11c, consensus 13c
Reports Q1 revenue $181.27M, consensus $171.41M. Marc D. Grodman, MD, CEO, commented, " On our earnings call in December 2013 we provided guidance that our Q1 earnings would be about half those of the prior fiscal year, which was 31c. If it had not been for the weather, that was a solid assessment of where we would be, around 16c when the 5c per share weather factor is taken into consideration."
News For BRLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
11:12 EDTBRLIOPKO granted early termination of waiting period for Bio-Reference acquisition
OPKO Health (OPK) and Bio-Reference Laboratories (BRLI) announced that early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has been granted, effective July 1, for OPKO's planned acquisition of Bio-Reference. Expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the merger. The transaction remains subject to other closing conditions, including the approval of Bio-Reference shareholders. The parties continue to expect that this transaction will close during the second half of 2015.
June 21, 2015
14:16 EDTBRLIOPKO Health shares look pricey, Barron's says
Investors should steer clear of OPKO Health (OPK) and Bio-Reference Labs (BRLI) in light of their recent merger agreement, Barron's contends in a feature article. Though OPKO hopes to push its prostate cancer test, similar products have performed poorly on the market, and Barron's advises "only those who believe that [CEO and chairman Phillip Frost] can work miracles" to own the stock. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use